199.59
0.93%
1.84
Precedente Chiudi:
$197.75
Aprire:
$200.05
Volume 24 ore:
238.55K
Relative Volume:
0.34
Capitalizzazione di mercato:
$10.63B
Reddito:
$4.08B
Utile/perdita netta:
$431.79M
Rapporto P/E:
21.17
EPS:
9.43
Flusso di cassa netto:
$486.92M
1 W Prestazione:
+6.22%
1M Prestazione:
+9.59%
6M Prestazione:
-8.11%
1 anno Prestazione:
+2.51%
Charles River Laboratories International Inc Stock (CRL) Company Profile
Nome
Charles River Laboratories International Inc
Settore
Industria
Telefono
781-222-6000
Indirizzo
251 BALLARDVALE ST, WILMINGTON, MA
Confronta CRL con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
CRL
Charles River Laboratories International Inc
|
199.59 | 10.63B | 4.08B | 431.79M | 486.92M | 9.43 |
TMO
Thermo Fisher Scientific Inc
|
521.66 | 199.82B | 42.37B | 6.14B | 7.78B | 15.26 |
DHR
Danaher Corp
|
238.83 | 173.66B | 23.74B | 3.89B | 4.98B | 7.93 |
A
Agilent Technologies Inc
|
138.14 | 38.64B | 6.51B | 1.29B | 1.37B | 3.82 |
IQV
Iqvia Holdings Inc
|
201.43 | 36.52B | 15.32B | 1.41B | 1.96B | 5.95 |
IDXX
Idexx Laboratories Inc
|
421.76 | 34.55B | 3.84B | 866.24M | 792.60M | 9.80 |
Charles River Laboratories International Inc Stock (CRL) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-18 | Downgrade | CLSA | Hold → Underperform |
2024-11-07 | Aggiornamento | CLSA | Underperform → Hold |
2024-10-23 | Iniziato | CLSA | Underperform |
2024-10-14 | Iniziato | Redburn Atlantic | Sell |
2024-10-07 | Downgrade | Evercore ISI | Outperform → In-line |
2024-10-02 | Downgrade | BofA Securities | Buy → Neutral |
2024-10-01 | Downgrade | Citigroup | Neutral → Sell |
2024-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
2024-08-08 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-06-28 | Downgrade | Argus | Buy → Hold |
2024-06-07 | Iniziato | Mizuho | Neutral |
2024-06-06 | Iniziato | Goldman | Buy |
2024-02-15 | Downgrade | Guggenheim | Buy → Neutral |
2023-09-13 | Iniziato | TD Cowen | Market Perform |
2023-07-10 | Downgrade | Citigroup | Buy → Neutral |
2023-02-23 | Aggiornamento | Guggenheim | Neutral → Buy |
2023-01-12 | Downgrade | Jefferies | Buy → Hold |
2022-09-30 | Aggiornamento | Jefferies | Hold → Buy |
2022-08-25 | Iniziato | Credit Suisse | Outperform |
2022-08-04 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2022-05-24 | Iniziato | Guggenheim | Neutral |
2022-04-25 | Downgrade | Jefferies | Buy → Hold |
2022-04-07 | Iniziato | Stephens | Overweight |
2022-02-17 | Reiterato | BofA Securities | Buy |
2022-02-17 | Aggiornamento | Citigroup | Neutral → Buy |
2022-02-17 | Reiterato | Deutsche Bank | Buy |
2022-02-17 | Reiterato | Morgan Stanley | Overweight |
2022-02-17 | Reiterato | UBS | Buy |
2021-08-05 | Ripresa | Credit Suisse | Neutral |
2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
2020-09-10 | Aggiornamento | Jefferies | Hold → Buy |
2020-07-01 | Aggiornamento | BofA Securities | Neutral → Buy |
2020-05-13 | Aggiornamento | UBS | Neutral → Buy |
2020-04-21 | Downgrade | Jefferies | Buy → Hold |
2020-03-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2020-03-02 | Iniziato | Deutsche Bank | Buy |
2020-02-18 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
2020-01-10 | Aggiornamento | Goldman | Neutral → Buy |
2020-01-08 | Iniziato | Wells Fargo | Overweight |
2020-01-07 | Iniziato | Citigroup | Buy |
2019-10-18 | Downgrade | BofA/Merrill | Buy → Neutral |
2019-06-10 | Iniziato | SVB Leerink | Outperform |
2019-04-30 | Ripresa | Evercore ISI | Outperform |
2018-12-14 | Iniziato | Deutsche Bank | Buy |
2018-10-09 | Iniziato | UBS | Neutral |
2018-08-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
2018-07-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2018-06-15 | Aggiornamento | KeyBanc Capital Mkts | Sector Weight → Overweight |
2018-02-14 | Aggiornamento | SunTrust | Hold → Buy |
Mostra tutto
Charles River Laboratories International Inc Borsa (CRL) Ultime notizie
Mudita Advisors LLP Decreases Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles Schwab Investment Management Inc. Purchases 32,311 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
While shareholders of Charles River Laboratories International (NYSE:CRL) are in the red over the last three years, underlying earnings have actually grown - Simply Wall St
Charles River labs accused of exploiting loophole to move monkeys through Canada - Montreal Gazette
Charles River Labs shares target cut, rating held on Q2 results - Investing.com Canada
Charles River Laboratories International Inc (CRL) Stock Price U - GuruFocus.com
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Bought by Citigroup Inc. - MarketBeat
Horizon Kinetics Asset Management LLC Sells 45,619 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Receives Average Rating of "Reduce" from Analysts - MarketBeat
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Sells 63,588 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Large Molecule Bioanalytical Technologies Market Research Explores Drivers And Growth Report 2033 - WhaTech
Lathrop Investment Management Corp Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
King Luther Capital Management Corp Sells 252,657 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Layoff Tracker: J&J, Merck Trimming Workforces in China - BioSpace
Brown Capital Management LLC Sells 13,542 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Medical Device Testing Services Market Growth, Size, Trends, - openPR
Charles River Laboratories To Present At Jefferies London Healthcare Conference; Webcast At 9:00 AM - Nasdaq
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by Premier Fund Managers Ltd - MarketBeat
Charles River Labs closes several locations, 1,300+ jobs cut in cost saving initiative - MSN
Major Player in the Biomarker Clinical Phase Outsourcing - openPR
Drug Discovery Outsourcing Services Market to Achieve a Superb - openPR
Natixis Advisors LLC Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories: Not The Right Time To Own At This Point In The Cycle - Seeking Alpha
Bioprocess Validation Market to Witness 9.10% CAGR by 2031 | SkyQuest Technology - Benzinga
Thrivent Financial for Lutherans Decreases Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mawer Investment Management Ltd. - MarketBeat
CLSA Downgrades Charles River Laboratories International (NYSE:CRL) to Underperform - MarketBeat
Sumitomo Mitsui Trust Group Inc. Grows Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Mizuho Securities USA LLC Buys 92,895 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
KBC Group NV Has $16.66 Million Stake in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Holdings Decreased by Victory Capital Management Inc. - MarketBeat
Entropy Technologies LP Reduces Position in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Entropy Technologies LP Trims Holdings in Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Empower Advisory Group LLC Sells 3,497 Shares of Charles River Laboratories International, Inc. (NYSE:CRL) - MarketBeat
Charles River Labs to close Skokie office - Crain's Chicago Business
Charles River Laboratories To Present At UBS Global Healthcare Conference; Webcast At 1:15 PM ET - Nasdaq
Charles River Laboratories International, Inc. (NYSE:CRL) Shares Purchased by WCM Investment Management LLC - MarketBeat
Charles River Laboratories International, Inc. (NYSE:CRL) Position Lowered by Amalgamated Bank - MarketBeat
Tranche Update on Charles River Laboratories International, Inc.'s Equity Buyback Plan announced on August 7, 2024. - Marketscreener.com
Genotoxicity Tests Market Trends Detailed Research and Projected Growth through 2032 - WICZ
Charles River Laboratories to Present at UBS and Jefferies Conferences - sharewise
Charles River Laboratories International (NYSE:CRL) Stock Price Expected to Rise, TD Cowen Analyst Says - MarketBeat
Charles River Laboratories International Inc Azioni (CRL) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):